No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents

Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study

(2016) P Jensen et al.   ACTA DERMATO-VENEREOLOGICA

Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study

(2016) A. Egeberg et al.   BRITISH JOURNAL OF DERMATOLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Ixekizumab: First Global Approval

(2016) Anthony Markham   DRUGS

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

(2016) Melissa J. Danesh et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis

(2016) Y. Umezawa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab: First Global Approval

(2015) Mark Sanford et al.   DRUGS

The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries

(2015) Florence J. Dalgard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial

(2015) M. Augustin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug

(2015) Charlie Schmidt   NATURE BIOTECHNOLOGY

Targeting the IL-17–TH17 pathway

(2015) Hilary S. Bartlett et al.   NATURE REVIEWS DRUG DISCOVERY

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial

(2014) B. Zhu et al.   BRITISH JOURNAL OF DERMATOLOGY

The common inflammatory etiology of depression and cognitive impairment: a therapeutic target

(2014) David J Allison et al.   Journal of Neuroinflammation

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

(2014) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation: a mechanism of depression?

(2014) Qiu-Qin Han et al.   Neuroscience Bulletin

Interleukin-17 inhibits Adult Hippocampal Neurogenesis

(2014) Qiang Liu et al.   Scientific Reports

Poststroke Neuropsychiatric Symptoms: Relationships with IL-17 and Oxidative Stress

(2014) W. Swardfager et al.   Biomed Research International

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

(2013) K.B. Gordon et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-17 targeted therapies for psoriasis

(2013) Andrea Chiricozzi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inflammatory T Helper 17 Cells Promote Depression-like Behavior in Mice

(2012) Eléonore Beurel et al.   BIOLOGICAL PSYCHIATRY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune system to brain signaling: Neuropsychopharmacological implications

(2011) Lucile Capuron et al.   PHARMACOLOGY & THERAPEUTICS

The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis

(2010) CHOSIDOW OLIVIER et al.   ARCHIVES OF DERMATOLOGY

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression

(2009) Andrew H. Miller et al.   BIOLOGICAL PSYCHIATRY

An overview of IL-17 function and signaling

(2008) Sarah L. Gaffen   CYTOKINE

Structure–function relationships in the IL-17 receptor: Implications for signal transduction and therapy

(2008) Fang Shen et al.   CYTOKINE

From inflammation to sickness and depression: when the immune system subjugates the brain

(2007) Robert Dantzer et al.   NATURE REVIEWS NEUROSCIENCE